APO Research
Talk to an analyst

APO RESEARCH · REPORT

GLP-1 Drug

Glucagon-like peptide-1 (GLP-1) drugs are peptide therapeutics that mimic or potentiate the actions of endogenous GLP-1 at the GLP-1 receptor, a class-B G-protein–coupled receptor expressed on pancreatic islet cells, in the gastrointestinal tract, and in the central and cardiovascular systems. Pharmacologically they restore or amplify the physiologic “incretin effect”: in hyperglycaemic states they enhance glucose-dependent insulin secretion from β-cells, suppress inappropriate glucagon from α-cells, slow gastric emptying early in treatment, and reduce appetite via hypothalamic and brainstem pathways. Because their insulinotropic action is glucose-dependent, GLP-1 receptor agonists (GLP-1RAs) have a low intrinsic risk of hypoglycaemia unless combined with insulin or insulin secretagogues, while their gastrointestinal effects (nausea, vomiting, diarrhoea) are class-typical, dose-related and mitigated by stepwise titration.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Glucagon-like peptide-1 (GLP-1) drugs are peptide therapeutics that mimic or potentiate the actions of endogenous GLP-1 at the GLP-1 receptor, a class-B G-protein–coupled receptor expressed on pancreatic islet cells, in the gastrointestinal tract, and in the central and cardiovascular systems. Pharmacologically they restore or amplify the physiologic “incretin effect”: in hyperglycaemic states they enhance glucose-dependent insulin secretion from β-cells, suppress inappropriate glucagon from α-cells, slow gastric emptying early in treatment, and reduce appetite via hypothalamic and brainstem pathways. Because their insulinotropic action is glucose-dependent, GLP-1 receptor agonists (GLP-1RAs) have a low intrinsic risk of hypoglycaemia unless combined with insulin or insulin secretagogues, while their gastrointestinal effects (nausea, vomiting, diarrhoea) are class-typical, dose-related and mitigated by stepwise titration.

At the molecular level the class spans two lineages. Exendin-based agents (e.g., exenatide and lixisenatide) derive from exendin-4 and are naturally DPP-4–resistant. Human-sequence analogues (e.g., liraglutide, semaglutide) and fusion constructs (e.g., dulaglutide) introduce substitutions or conjugations that protect the peptide from dipeptidyl peptidase-4 and renal clearance and, in long-acting variants, promote albumin binding or extend half-life through Fc fusion or PEGylation. Liraglutide carries a C16 fatty-acid side chain to bind albumin; semaglutide combines a DPP-4–resistant substitution with a C18 fatty-acid–spacer for strong albumin binding; dulaglutide fuses two GLP-1 analog moieties to a modified IgG4 Fc to slow elimination; exenatide extended-release incorporates the peptide into PLGA microspheres for weekly release; oral semaglutide employs the absorption enhancer SNAC to enable gastric uptake of an otherwise parenteral peptide. These structural strategies drive pharmacokinetics and clinical phenotype: short-exposure agents exert a proportionally larger post-prandial effect (via gastric emptying), while sustained-exposure agents have stronger fasting-glucose effects and smoother 24-hour control.

For clarity in product mapping, the marketed GLP-1RA portfolio covers human-sequence and exendin-based APIs across daily, weekly and oral modalities. Representative single-agent brands include exenatide immediate-release (Byetta) and extended-release (Bydureon/BCise), lixisenatide (Adlyxin/Lyxumia), liraglutide daily injection for diabetes (Victoza) and for weight management (Saxenda), dulaglutide weekly injection (Trulicity), semaglutide weekly injection for diabetes (Ozempic) and for weight management and cardiovascular risk reduction in appropriate populations (Wegovy), and semaglutide oral tablets (Rybelsus). Fixed-ratio combinations pair a GLP-1RA with basal insulin—insulin degludec + liraglutide (IDegLira; Xultophy) and insulin glargine + lixisenatide (iGlarLixi; Soliqua/Suliqua)—to streamline intensification in type 2 diabetes. Regional markets also include China domestic GLP-1RAs such as beinaglutide (short-acting, human-sequence GLP-1[7-36]) and PEG-loxenatide (weekly PEGylated exendin analogue). Dual- or multi-receptor incretin agonists exist but, by definition, sit outside the “GLP-1-only” class.

Indications in routine practice cluster into three labeled application domains. In type 2 diabetes (T2D), GLP-1RAs are used as an adjunct to diet and exercise as monotherapy when metformin is inappropriate, or in combination with oral agents and/or insulin when additional glycaemic control is needed; some agents have paediatric T2D labeling. In chronic weight management (Obesity), higher-dose liraglutide and semaglutide carry indications for adults with obesity or overweight with weight-related comorbidities, and certain labels extend to adolescents. In cardiovascular risk reduction (CV risk), specific products are approved to reduce major adverse cardiovascular events in adults with T2D and established atherosclerotic cardiovascular disease, and selected high-dose semaglutide carries a cardiovascular-risk reduction label in adults with established CVD who are overweight or obese. Risk-reduction labeling in chronic kidney disease for T2D populations is best treated as a T2D sub-label rather than a separate application domain. These labeled uses are product-specific; they should not be generalized across the entire class without reference to the individual label.

Mechanistically, receptor activation increases intracellular cAMP and engages PKA and Epac2 pathways, amplifying the β-cell exocytotic response to glucose, modulating β-cell gene expression and survival signals, and repressing α-cell glucagon in hyperglycaemia. In the gut, vagal and local effects slow gastric emptying at treatment initiation, which blunts post-prandial glucose excursions; this effect often attenuates with chronic dosing for long-acting agents. In the CNS, activation of POMC/CART neurons and downstream circuits decreases appetite and energy intake; peripheral effects on adipose tissue, liver and kidney contribute to weight loss and natriuresis. Cardiometabolic benefits observed in outcome studies likely reflect an integrated impact on weight, blood pressure, glycaemia, lipids and vascular inflammation rather than a single pathway.

Pharmacology and formulation determine dose cadence and “type.” In market segmentation, short-acting agents are those given daily or multiple times per day and are characterized by prominent post-prandial control; examples include exenatide immediate-release, lixisenatide and daily liraglutide. Long-acting agents deliver sustained exposure with weekly administration or, in the case of oral semaglutide, long pharmacodynamic activity despite daily dosing; examples include dulaglutide, semaglutide subcutaneous weekly, exenatide extended-release and PEG-loxenatide. Fixed-ratio combinations couple a GLP-1RA with basal insulin to produce complementary fasting and prandial control in a single daily injection. Oral semaglutide provides a non-injectable option but introduces administration rules—fasting state, limited water intake, and a wait period before food or other medications—that can affect real-world adherence.

Adherence is driven by device, titration and tolerability. Weekly autoinjectors lower injection burden and generally improve persistence compared with daily injectables, but gastrointestinal tolerability still requires careful uptitration. Oral semaglutide avoids needles yet trades that advantage for fasting-administration complexity; some patients prefer daily pens for simplicity once trained. Across the class, gradual dose escalation from a low introductory dose is central to minimizing GI symptoms. Most agents have low intrinsic hypoglycaemia risk when used without insulin or sulfonylureas; combination use often necessitates down-titration of the concomitant secretagogue or basal insulin as glycaemia improves. Class warnings include a contraindication in patients with personal or family history of medullary thyroid carcinoma or MEN2 for labels that carry a C-cell tumor warning, caution in patients with prior pancreatitis, and attention to gallbladder disease signals. Slowed gastric emptying can alter the absorption of co-administered oral drugs with a narrow therapeutic window, which warrants timing adjustments in practice. Rapid glycaemic improvement in susceptible patients may transiently worsen retinopathy and should be monitored.

From a development standpoint the class evolved from twice-daily exendin-based injections to weekly sustained-exposure analogues and, most recently, to high-dose weight-management regimens and an oral tablet formulation. Cardiovascular-outcomes programs transformed GLP-1RAs from pure glucose-lowering agents into cardiometabolic medicines with event-reduction labels for selected products and populations. Manufacturing has scaled from conventional peptide synthesis and sterile vialing to sophisticated autoinjector pens, PLGA microsphere encapsulation and tablet technologies that enable gastric uptake; these choices shape supply chains, dose flexibility and cost profiles.

In sum, GLP-1 drugs are a coherent but diverse class unified by a glucose-dependent incretin mechanism and differentiated by structure, exposure profile, dose form and label. The practical taxonomy that matters in clinical and market analysis is simple and serviceable: type by dosing profile (Short-acting; Long-acting; Fixed-ratio combo), modality by route (injection; oral), and application by labeled domain (T2D; Obesity; CV risk). Within that frame the choice of agent is a balance among glycaemic and weight targets, cardiovascular risk status, patient preference for frequency and route, and the operational realities of access, price and supply.

Selected research

Market Outlook & Growth Opportunities

Global GLP-1 Drug Market Outlook and Growth Opportunities 2026

21 December 2025199 pages

Choose your research edition.

Industry ResearchGLP-1 Drug Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal GLP-1 Drug Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal GLP-1 Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GLP-1 Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal GLP-1 Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

Glucagon-like peptide-1 (GLP-1) drugs are peptide therapeutics that mimic or potentiate the actions of endogenous GLP-1 at the GLP-1 receptor, a class-B G-protein–coupled receptor expressed on pancreatic islet cells, in the gastrointestinal tract, and in the central and cardiovascular systems. Pharmacologically they restore or amplify the physiologic “incretin effect”: in hyperglycaemic states they enhance glucose-dependent insulin secretion from β-cells, suppress inappropriate glucagon from α-cells, slow gastric emptying early in treatment, and reduce appetite via hypothalamic and brainstem pathways. Because their insulinotropic action is glucose-dependent, GLP-1 receptor agonists (GLP-1RAs) have a low intrinsic risk of hypoglycaemia unless combined with insulin or insulin secretagogues, while their gastrointestinal effects (nausea, vomiting, diarrhoea) are class-typical, dose-related and mitigated by stepwise titration.

At the molecular level the class spans two lineages. Exendin-based agents (e.g., exenatide and lixisenatide) derive from exendin-4 and are naturally DPP-4–resistant. Human-sequence analogues (e.g., liraglutide, semaglutide) and fusion constructs (e.g., dulaglutide) introduce substitutions or conjugations that protect the peptide from dipeptidyl peptidase-4 and renal clearance and, in long-acting variants, promote albumin binding or extend half-life through Fc fusion or PEGylation. Liraglutide carries a C16 fatty-acid side chain to bind albumin; semaglutide combines a DPP-4–resistant substitution with a C18 fatty-acid–spacer for strong albumin binding; dulaglutide fuses two GLP-1 analog moieties to a modified IgG4 Fc to slow elimination; exenatide extended-release incorporates the peptide into PLGA microspheres for weekly release; oral semaglutide employs the absorption enhancer SNAC to enable gastric uptake of an otherwise parenteral peptide. These structural strategies drive pharmacokinetics and clinical phenotype: short-exposure agents exert a proportionally larger post-prandial effect (via gastric emptying), while sustained-exposure agents have stronger fasting-glucose effects and smoother 24-hour control.

For clarity in product mapping, the marketed GLP-1RA portfolio covers human-sequence and exendin-based APIs across daily, weekly and oral modalities. Representative single-agent brands include exenatide immediate-release (Byetta) and extended-release (Bydureon/BCise), lixisenatide (Adlyxin/Lyxumia), liraglutide daily injection for diabetes (Victoza) and for weight management (Saxenda), dulaglutide weekly injection (Trulicity), semaglutide weekly injection for diabetes (Ozempic) and for weight management and cardiovascular risk reduction in appropriate populations (Wegovy), and semaglutide oral tablets (Rybelsus). Fixed-ratio combinations pair a GLP-1RA with basal insulin—insulin degludec + liraglutide (IDegLira; Xultophy) and insulin glargine + lixisenatide (iGlarLixi; Soliqua/Suliqua)—to streamline intensification in type 2 diabetes. Regional markets also include China domestic GLP-1RAs such as beinaglutide (short-acting, human-sequence GLP-1[7-36]) and PEG-loxenatide (weekly PEGylated exendin analogue). Dual- or multi-receptor incretin agonists exist but, by definition, sit outside the “GLP-1-only” class.

Read the full market overview

Indications in routine practice cluster into three labeled application domains. In type 2 diabetes (T2D), GLP-1RAs are used as an adjunct to diet and exercise as monotherapy when metformin is inappropriate, or in combination with oral agents and/or insulin when additional glycaemic control is needed; some agents have paediatric T2D labeling. In chronic weight management (Obesity), higher-dose liraglutide and semaglutide carry indications for adults with obesity or overweight with weight-related comorbidities, and certain labels extend to adolescents. In cardiovascular risk reduction (CV risk), specific products are approved to reduce major adverse cardiovascular events in adults with T2D and established atherosclerotic cardiovascular disease, and selected high-dose semaglutide carries a cardiovascular-risk reduction label in adults with established CVD who are overweight or obese. Risk-reduction labeling in chronic kidney disease for T2D populations is best treated as a T2D sub-label rather than a separate application domain. These labeled uses are product-specific; they should not be generalized across the entire class without reference to the individual label.

Mechanistically, receptor activation increases intracellular cAMP and engages PKA and Epac2 pathways, amplifying the β-cell exocytotic response to glucose, modulating β-cell gene expression and survival signals, and repressing α-cell glucagon in hyperglycaemia. In the gut, vagal and local effects slow gastric emptying at treatment initiation, which blunts post-prandial glucose excursions; this effect often attenuates with chronic dosing for long-acting agents. In the CNS, activation of POMC/CART neurons and downstream circuits decreases appetite and energy intake; peripheral effects on adipose tissue, liver and kidney contribute to weight loss and natriuresis. Cardiometabolic benefits observed in outcome studies likely reflect an integrated impact on weight, blood pressure, glycaemia, lipids and vascular inflammation rather than a single pathway.

Pharmacology and formulation determine dose cadence and “type.” In market segmentation, short-acting agents are those given daily or multiple times per day and are characterized by prominent post-prandial control; examples include exenatide immediate-release, lixisenatide and daily liraglutide. Long-acting agents deliver sustained exposure with weekly administration or, in the case of oral semaglutide, long pharmacodynamic activity despite daily dosing; examples include dulaglutide, semaglutide subcutaneous weekly, exenatide extended-release and PEG-loxenatide. Fixed-ratio combinations couple a GLP-1RA with basal insulin to produce complementary fasting and prandial control in a single daily injection. Oral semaglutide provides a non-injectable option but introduces administration rules—fasting state, limited water intake, and a wait period before food or other medications—that can affect real-world adherence.

Adherence is driven by device, titration and tolerability. Weekly autoinjectors lower injection burden and generally improve persistence compared with daily injectables, but gastrointestinal tolerability still requires careful uptitration. Oral semaglutide avoids needles yet trades that advantage for fasting-administration complexity; some patients prefer daily pens for simplicity once trained. Across the class, gradual dose escalation from a low introductory dose is central to minimizing GI symptoms. Most agents have low intrinsic hypoglycaemia risk when used without insulin or sulfonylureas; combination use often necessitates down-titration of the concomitant secretagogue or basal insulin as glycaemia improves. Class warnings include a contraindication in patients with personal or family history of medullary thyroid carcinoma or MEN2 for labels that carry a C-cell tumor warning, caution in patients with prior pancreatitis, and attention to gallbladder disease signals. Slowed gastric emptying can alter the absorption of co-administered oral drugs with a narrow therapeutic window, which warrants timing adjustments in practice. Rapid glycaemic improvement in susceptible patients may transiently worsen retinopathy and should be monitored.

From a development standpoint the class evolved from twice-daily exendin-based injections to weekly sustained-exposure analogues and, most recently, to high-dose weight-management regimens and an oral tablet formulation. Cardiovascular-outcomes programs transformed GLP-1RAs from pure glucose-lowering agents into cardiometabolic medicines with event-reduction labels for selected products and populations. Manufacturing has scaled from conventional peptide synthesis and sterile vialing to sophisticated autoinjector pens, PLGA microsphere encapsulation and tablet technologies that enable gastric uptake; these choices shape supply chains, dose flexibility and cost profiles.

In sum, GLP-1 drugs are a coherent but diverse class unified by a glucose-dependent incretin mechanism and differentiated by structure, exposure profile, dose form and label. The practical taxonomy that matters in clinical and market analysis is simple and serviceable: type by dosing profile (Short-acting; Long-acting; Fixed-ratio combo), modality by route (injection; oral), and application by labeled domain (T2D; Obesity; CV risk). Within that frame the choice of agent is a balance among glycaemic and weight targets, cardiovascular risk status, patient preference for frequency and route, and the operational realities of access, price and supply.

The global GLP-1 Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for GLP-1 Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GLP-1 Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Asia Pacific market for GLP-1 Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the GLP-1 Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the GLP-1 Drug market include Novo Nordisk, Eli Lilly, Sanofi, Teva, Jiangsu Hansoh Pharmaceutical, Huadong Medicine, Benemae Pharmaceutical, Tonghua Dongbao Pharma and Chia Tai-Tianqing Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global GLP-1 Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GLP-1 Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GLP-1 Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the GLP-1 Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

GLP-1 Drug Segment by Company

Novo Nordisk

Eli Lilly

Sanofi

Teva

Jiangsu Hansoh Pharmaceutical

Huadong Medicine

Benemae Pharmaceutical

Tonghua Dongbao Pharma

Chia Tai-Tianqing Pharmaceutical

AstraZeneca

GLP-1 Drug Segment by Type

Short-acting

Long-acting

GLP-1 Drug Segment by Indications

T2D

CV risk

Obesity

GLP-1 Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global GLP-1 Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions GLP-1 Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify GLP-1 Drug significant trends, drivers, influence factors in global and regions.

6. To analyze GLP-1 Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the GLP-1 Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GLP-1 Drug industry.

Chapter 3: Detailed analysis of GLP-1 Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of GLP-1 Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of GLP-1 Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. GLP-1 Drug Industry Trends Table 2. GLP-1 Drug Industry Drivers Table 3. GLP-1 Drug Industry Opportunities and Challenges Table 4. GLP-1 Drug Industry Restraints Table 5. Global GLP-1 Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global GLP-1 Drug Revenue Share by Company (2021-2026) Table 7. Global GLP-1 Drug Sales Volume by Company (Sales (k PMT)) & (2021-2026) Table 8. Global GLP-1 Drug Sales Volume Share by Company (2021-2026) Table 9. Global GLP-1 Drug Average Price (Net Price (USD/PMT)) of Company (2021-2026) Table 10. Global GLP-1 Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global GLP-1 Drug Key Company Manufacturing Base & Headquarters Table 12. Global GLP-1 Drug Company, Product Type & Application Table 13. Global GLP-1 Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global GLP-1 Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Short-acting Table 18. Significant Companies of Long-acting Table 19. Global GLP-1 Drug Sales Volume by Type 2021 VS 2025 VS 2032 (Sales (k PMT)) Table 20. Global GLP-1 Drug Sales Volume by Type (2021-2026) & (Sales (k PMT)) Table 21. Global GLP-1 Drug Sales Volume by Type (2027-2032) & (Sales (k PMT)) Table 22. Global GLP-1 Drug Sales Volume Share by Type (2021-2026) Table 23. Global GLP-1 Drug Sales Volume Share by Type (2027-2032) Table 24. Global GLP-1 Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global GLP-1 Drug Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global GLP-1 Drug Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global GLP-1 Drug Sales Value Share by Type (2021-2026) Table 28. Global GLP-1 Drug Sales Value Share by Type (2027-2032) Table 29. Significant Companies of T2D Table 30. Significant Companies of CV risk Table 31. Significant Companies of Obesity Table 32. Global GLP-1 Drug Sales Volume by Application 2021 VS 2025 VS 2032 (Sales (k PMT)) Table 33. Global GLP-1 Drug Sales Volume by Application (2021-2026) & (Sales (k PMT)) Table 34. Global GLP-1 Drug Sales Volume by Application (2027-2032) & (Sales (k PMT)) Table 35. Global GLP-1 Drug Sales Volume Share by Application (2021-2026) Table 36. Global GLP-1 Drug Sales Volume Share by Application (2027-2032) Table 37. Global GLP-1 Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global GLP-1 Drug Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global GLP-1 Drug Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global GLP-1 Drug Sales Value Share by Application (2021-2026) Table 41. Global GLP-1 Drug Sales Value Share by Application (2027-2032) Table 42. Global GLP-1 Drug Sales by Region: 2021 VS 2025 VS 2032 (Sales (k PMT)) Table 43. Global GLP-1 Drug Sales by Region (2021-2026) & (Sales (k PMT)) Table 44. Global GLP-1 Drug Sales Market Share by Region (2021-2026) Table 45. Global GLP-1 Drug Sales by Region (2027-2032) & (Sales (k PMT)) Table 46. Global GLP-1 Drug Sales Market Share by Region (2027-2032) Table 47. Global GLP-1 Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global GLP-1 Drug Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global GLP-1 Drug Sales Value Share by Region (2021-2026) Table 50. Global GLP-1 Drug Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global GLP-1 Drug Sales Value Share by Region (2027-2032) Table 52. Global GLP-1 Drug Market Average Price (Net Price (USD/PMT)) by Region (2021-2026) Table 53. Global GLP-1 Drug Market Average Price (Net Price (USD/PMT)) by Region (2027-2032) Table 54. Global GLP-1 Drug Sales by Country: 2021 VS 2025 VS 2032 (Sales (k PMT)) Table 55. Global GLP-1 Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 57. Global GLP-1 Drug Sales Market Share by Country (2021-2026) Table 58. Global GLP-1 Drug Sales by Country (2027-2032) & (Sales (k PMT)) Table 59. Global GLP-1 Drug Sales Market Share by Country (2027-2032) Table 60. Global GLP-1 Drug Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global GLP-1 Drug Sales Value Market Share by Country (2021-2026) Table 62. Global GLP-1 Drug Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global GLP-1 Drug Sales Value Market Share by Country (2027-2032) Table 64. Novo Nordisk Company Information Table 65. Novo Nordisk Business Overview Table 66. Novo Nordisk GLP-1 Drug Sales (Sales (k PMT)), Value (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 67. Novo Nordisk GLP-1 Drug Product Portfolio Table 68. Novo Nordisk Recent Development Table 69. Eli Lilly Company Information Table 70. Eli Lilly Business Overview Table 71. Eli Lilly GLP-1 Drug Sales (Sales (k PMT)), Value (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 72. Eli Lilly GLP-1 Drug Product Portfolio Table 73. Eli Lilly Recent Development Table 74. Sanofi Company Information Table 75. Sanofi Business Overview Table 76. Sanofi GLP-1 Drug Sales (Sales (k PMT)), Value (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 77. Sanofi GLP-1 Drug Product Portfolio Table 78. Sanofi Recent Development Table 79. Teva Company Information Table 80. Teva Business Overview Table 81. Teva GLP-1 Drug Sales (Sales (k PMT)), Value (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 82. Teva GLP-1 Drug Product Portfolio Table 83. Teva Recent Development Table 84. Jiangsu Hansoh Pharmaceutical Company Information Table 85. Jiangsu Hansoh Pharmaceutical Business Overview Table 86. Jiangsu Hansoh Pharmaceutical GLP-1 Drug Sales (Sales (k PMT)), Value (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 87. Jiangsu Hansoh Pharmaceutical GLP-1 Drug Product Portfolio Table 88. Jiangsu Hansoh Pharmaceutical Recent Development Table 89. Huadong Medicine Company Information Table 90. Huadong Medicine Business Overview Table 91. Huadong Medicine GLP-1 Drug Sales (Sales (k PMT)), Value (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 92. Huadong Medicine GLP-1 Drug Product Portfolio Table 93. Huadong Medicine Recent Development Table 94. Benemae Pharmaceutical Company Information Table 95. Benemae Pharmaceutical Business Overview Table 96. Benemae Pharmaceutical GLP-1 Drug Sales (Sales (k PMT)), Value (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 97. Benemae Pharmaceutical GLP-1 Drug Product Portfolio Table 98. Benemae Pharmaceutical Recent Development Table 99. Tonghua Dongbao Pharma Company Information Table 100. Tonghua Dongbao Pharma Business Overview Table 101. Tonghua Dongbao Pharma GLP-1 Drug Sales (Sales (k PMT)), Value (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 102. Tonghua Dongbao Pharma GLP-1 Drug Product Portfolio Table 103. Tonghua Dongbao Pharma Recent Development Table 104. Chia Tai-Tianqing Pharmaceutical Company Information Table 105. Chia Tai-Tianqing Pharmaceutical Business Overview Table 106. Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Sales (Sales (k PMT)), Value (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 107. Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Product Portfolio Table 108. Chia Tai-Tianqing Pharmaceutical Recent Development Table 109. AstraZeneca Company Information Table 110. AstraZeneca Business Overview Table 111. AstraZeneca GLP-1 Drug Sales (Sales (k PMT)), Value (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 112. AstraZeneca GLP-1 Drug Product Portfolio Table 113. AstraZeneca Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. GLP-1 Drug Distributors List Table 117. GLP-1 Drug Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. GLP-1 Drug Product Image Figure 2. Global GLP-1 Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GLP-1 Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global GLP-1 Drug Sales (2021-2032) & (Sales (k PMT)) Figure 5. Global GLP-1 Drug Sales Average Price (Net Price (USD/PMT)) & (2021-2032) Figure 6. Global GLP-1 Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Short-acting Image Figure 10. Long-acting Image Figure 11. Global GLP-1 Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (Sales (k PMT)) Figure 12. Global GLP-1 Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global GLP-1 Drug Sales Volume Share by Type (2021-2032) Figure 14. Global GLP-1 Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global GLP-1 Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global GLP-1 Drug Sales Value Share by Type (2021-2032) Figure 17. T2D Image Figure 18. CV risk Image Figure 19. Obesity Image Figure 20. Global GLP-1 Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (Sales (k PMT)) Figure 21. Global GLP-1 Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global GLP-1 Drug Sales Volume Share by Application (2021-2032) Figure 23. Global GLP-1 Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global GLP-1 Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global GLP-1 Drug Sales Value Share by Application (2021-2032) Figure 26. Global GLP-1 Drug Sales by Region: 2021 VS 2025 VS 2032 (Sales (k PMT)) Figure 27. Global GLP-1 Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global GLP-1 Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global GLP-1 Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America GLP-1 Drug Sales Value (2021-2032) & (US$ Million) Figure 31. North America GLP-1 Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe GLP-1 Drug Sales Value (2021-2032) & (US$ Million) Figure 33. Europe GLP-1 Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific GLP-1 Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific GLP-1 Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America GLP-1 Drug Sales Value (2021-2032) & (US$ Million) Figure 37. South America GLP-1 Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa GLP-1 Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa GLP-1 Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. GLP-1 Drug Value Chain Figure 125. Manufacturing Cost Structure Figure 126. GLP-1 Drug Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Short-acting
  • Long-acting
Applications
  • T2D
  • CV risk
  • Obesity
Companies covered
  • Novo Nordisk
  • Eli Lilly
  • Sanofi
  • Teva
  • Jiangsu Hansoh Pharmaceutical
  • Huadong Medicine
  • Benemae Pharmaceutical
  • Tonghua Dongbao Pharma
  • Chia Tai-Tianqing Pharmaceutical
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global GLP-1 Drug Sales Value (2021-2032)
  4. 1.2.2 Global GLP-1 Drug Sales Volume (2021-2032)
  5. 1.2.3 Global GLP-1 Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 GLP-1 Drug Market Dynamics
  1. 2.1 GLP-1 Drug Industry Trends
  2. 2.2 GLP-1 Drug Industry Drivers
  3. 2.3 GLP-1 Drug Industry Opportunities and Challenges
  4. 2.4 GLP-1 Drug Industry Restraints
3 GLP-1 Drug Market by Company
  1. 3.1 Global GLP-1 Drug Company Revenue Ranking in 2025
  2. 3.2 Global GLP-1 Drug Revenue by Company (2021-2026)
  3. 3.3 Global GLP-1 Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global GLP-1 Drug Average Price by Company (2021-2026)
  5. 3.5 Global GLP-1 Drug Company Ranking (2024-2026)
  6. 3.6 Global GLP-1 Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global GLP-1 Drug Company Product Type and Application
  8. 3.8 Global GLP-1 Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global GLP-1 Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 GLP-1 Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 GLP-1 Drug Market by Type
  1. 4.1 GLP-1 Drug Type Introduction
  2. 4.1.1 Short-acting
  3. 4.1.2 Long-acting
  4. 4.2 Global GLP-1 Drug Sales Volume by Type
  5. 4.2.1 Global GLP-1 Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global GLP-1 Drug Sales Volume by Type (2021-2032)
  7. 4.2.3 Global GLP-1 Drug Sales Volume Share by Type (2021-2032)
  8. 4.3 Global GLP-1 Drug Sales Value by Type
  9. 4.3.1 Global GLP-1 Drug Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global GLP-1 Drug Sales Value by Type (2021-2032)
  11. 4.3.3 Global GLP-1 Drug Sales Value Share by Type (2021-2032)
5 GLP-1 Drug Market by Application
  1. 5.1 GLP-1 Drug Application Introduction
  2. 5.1.1 T2D
  3. 5.1.2 CV risk
  4. 5.1.3 Obesity
  5. 5.2 Global GLP-1 Drug Sales Volume by Application
  6. 5.2.1 Global GLP-1 Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global GLP-1 Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global GLP-1 Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global GLP-1 Drug Sales Value by Application
  10. 5.3.1 Global GLP-1 Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global GLP-1 Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global GLP-1 Drug Sales Value Share by Application (2021-2032)
6 GLP-1 Drug Regional Sales and Value Analysis
  1. 6.1 Global GLP-1 Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GLP-1 Drug Sales by Region (2021-2032)
  3. 6.2.1 Global GLP-1 Drug Sales by Region: 2021-2026
  4. 6.2.2 Global GLP-1 Drug Sales by Region (2027-2032)
  5. 6.3 Global GLP-1 Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global GLP-1 Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global GLP-1 Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global GLP-1 Drug Sales Value by Region (2027-2032)
  9. 6.5 Global GLP-1 Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America GLP-1 Drug Sales Value (2021-2032)
  12. 6.6.2 North America GLP-1 Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe GLP-1 Drug Sales Value (2021-2032)
  15. 6.7.2 Europe GLP-1 Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific GLP-1 Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific GLP-1 Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America GLP-1 Drug Sales Value (2021-2032)
  21. 6.9.2 South America GLP-1 Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa GLP-1 Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa GLP-1 Drug Sales Value Share by Country, 2025 VS 2032
7 GLP-1 Drug Country-level Sales and Value Analysis
  1. 7.1 Global GLP-1 Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global GLP-1 Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global GLP-1 Drug Sales by Country (2021-2032)
  4. 7.3.1 Global GLP-1 Drug Sales by Country (2021-2026)
  5. 7.3.2 Global GLP-1 Drug Sales by Country (2027-2032)
  6. 7.4 Global GLP-1 Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global GLP-1 Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global GLP-1 Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA GLP-1 Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada GLP-1 Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico GLP-1 Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany GLP-1 Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France GLP-1 Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. GLP-1 Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy GLP-1 Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain GLP-1 Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia GLP-1 Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands GLP-1 Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries GLP-1 Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China GLP-1 Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan GLP-1 Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea GLP-1 Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India GLP-1 Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia GLP-1 Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia GLP-1 Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil GLP-1 Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina GLP-1 Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile GLP-1 Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia GLP-1 Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru GLP-1 Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia GLP-1 Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel GLP-1 Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE GLP-1 Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey GLP-1 Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran GLP-1 Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt GLP-1 Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novo Nordisk
  2. 8.1.1 Novo Nordisk Company Information
  3. 8.1.2 Novo Nordisk Business Overview
  4. 8.1.3 Novo Nordisk GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novo Nordisk GLP-1 Drug Product Portfolio
  6. 8.1.5 Novo Nordisk Recent Developments
  7. 8.2 Eli Lilly
  8. 8.2.1 Eli Lilly Company Information
  9. 8.2.2 Eli Lilly Business Overview
  10. 8.2.3 Eli Lilly GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly GLP-1 Drug Product Portfolio
  12. 8.2.5 Eli Lilly Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi GLP-1 Drug Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Teva
  20. 8.4.1 Teva Company Information
  21. 8.4.2 Teva Business Overview
  22. 8.4.3 Teva GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Teva GLP-1 Drug Product Portfolio
  24. 8.4.5 Teva Recent Developments
  25. 8.5 Jiangsu Hansoh Pharmaceutical
  26. 8.5.1 Jiangsu Hansoh Pharmaceutical Company Information
  27. 8.5.2 Jiangsu Hansoh Pharmaceutical Business Overview
  28. 8.5.3 Jiangsu Hansoh Pharmaceutical GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Jiangsu Hansoh Pharmaceutical GLP-1 Drug Product Portfolio
  30. 8.5.5 Jiangsu Hansoh Pharmaceutical Recent Developments
  31. 8.6 Huadong Medicine
  32. 8.6.1 Huadong Medicine Company Information
  33. 8.6.2 Huadong Medicine Business Overview
  34. 8.6.3 Huadong Medicine GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Huadong Medicine GLP-1 Drug Product Portfolio
  36. 8.6.5 Huadong Medicine Recent Developments
  37. 8.7 Benemae Pharmaceutical
  38. 8.7.1 Benemae Pharmaceutical Company Information
  39. 8.7.2 Benemae Pharmaceutical Business Overview
  40. 8.7.3 Benemae Pharmaceutical GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Benemae Pharmaceutical GLP-1 Drug Product Portfolio
  42. 8.7.5 Benemae Pharmaceutical Recent Developments
  43. 8.8 Tonghua Dongbao Pharma
  44. 8.8.1 Tonghua Dongbao Pharma Company Information
  45. 8.8.2 Tonghua Dongbao Pharma Business Overview
  46. 8.8.3 Tonghua Dongbao Pharma GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Tonghua Dongbao Pharma GLP-1 Drug Product Portfolio
  48. 8.8.5 Tonghua Dongbao Pharma Recent Developments
  49. 8.9 Chia Tai-Tianqing Pharmaceutical
  50. 8.9.1 Chia Tai-Tianqing Pharmaceutical Company Information
  51. 8.9.2 Chia Tai-Tianqing Pharmaceutical Business Overview
  52. 8.9.3 Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Product Portfolio
  54. 8.9.5 Chia Tai-Tianqing Pharmaceutical Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca GLP-1 Drug Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 GLP-1 Drug Value Chain Analysis
  2. 9.1.1 GLP-1 Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 GLP-1 Drug Sales Mode & Process
  6. 9.2 GLP-1 Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 GLP-1 Drug Distributors
  9. 9.2.3 GLP-1 Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst